

AGENDA

TIME	SUBJECT	SPEAKER
12:00 рм — 1:30 рм	Registration	
1:30 рм — 1:45 рм	Welcome and Introductions	Jody L. Green, PhD, CCRP – Director – Canadian Consumer Product and Pharmaceutical Safety Inc.
1:45 рм — 2:30 рм	The Global Mosaic: RADARS® System International Program Updates	
2:30 рм — 3:00 рм	Opioid Surveillance and Policy Evaluation: A Canadian Perspective	Tara Gomes Scientist – St. Michael's Hospital
3:00 рм — 3:30 рм	Break	
3:30 рм — 4:00 рм	Comparative Assessments of the Prescription Drug Abuse Climate in the European Union and the United States: Scientific, Regulatory, and Cultural Factors	Scott P. Novak, PhD Director and Senior Research Scientist, Substance Abuse Research and Treatment, Public Health Center – Battelle Memorial Institute
4:00 pm - 4:30 pm	Trends in Pharmaceutical Opioid Use in Australia: Increasing Exposure, Increasing Risk?	Louisa Degenhardt, PhD NHMRC Principal Research Fellow, National Drug & Alcohol Research Centre – University of New South Wales
4:30 рм — 5:00 рм	Panel Discussion and Summary	Jody L. Green, PhD, CCRP (Moderator) – Director – Canadian Consumer Product and Pharmaceutical Safety Inc.
5:00 рм	Closing Remarks	
5:00 рм — 7:00 рм	Networking Welcome Reception Georgetown University Room	



AGENDA

TIME	SUBJECT	SPEAKER
7:30 ам — 8:30 ам	Registration and Breakfast	
8:30 am – 9:30 am	Welcome and RADARS® System 2016 Data Updates	Richard C. Dart, MD, PhD Executive Director, RADARS® System — Denver Health and Hospital Authority
9:30 am — 10:00 am	Behind the Opioid Epidemic – Fentanyl, Immediate-Release Opioids, and Mortality	Janetta L. Iwanicki, MD Associate Medical Director, Rocky Mountain Poison & Drug Center – Denver Health and Hospital Authority
10:00 ам — 10:15 ам	Break	
10:15 ам — 11:15 ам	Darknet Drug Markets: Supply Chains, Stakeholders, and Opportunities for Public Health	Michael Gilbert, MPH Epidemico
		Nabarun Dasgupta, MPH, PhD Senior Scientist, RADARS® System – Denver Health and Hospital Authority
11:15 ам — 11:45 ам	ICER's Report on Comparative Value of Abuse Deterrent Formulations of Opioids: Draft Results	Richard Chapman, PhD Director of Health Economics – Institute for Clinical and Economic Review (ICER)
11:45 AM — 12:15 PM	Panel Discussion	Richard C. Dart, MD, PhD (Moderator) Executive Director, RADARS® System — Denver Health and Hospital Authority
12:15 рм — 1:15 рм	Lunch Break	



AGENDA

1:15 pm — 1:45 pm	Evaluating the Impact of Abuse Deterrent Formulations: Methodological Challenges in Postmarketing Data	Judy Staffa, PhD, RPh Associate Director for Public Health Initiatives, Office of Surveillance and Epidemiology – U.S. Food and Drug Administration
1:45 рм — 2:30 рм	Findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) Study: Monitoring the Impact of a Potentially Tamper-Resistant Formulation of Controlled-Release Oxycodone, Reformulated OxyContin®	Louisa Degenhardt, PhD NHMRC Principal Research Fellow, National Drug & Alcohol Research Centre – University of New South Wales
2:30 рм — 3:00 рм	RAPID Analysis of Routes of Administration: Oral to Non-Oral Transitions	Theodore J. Cicero, PhD John P. Feighner Professor of Psychiatry, Department of Psychiatry – Washington University in St. Louis School of Medicine
3:00 рм — 3:30 рм	Panel Discussion and Summary	Richard C. Dart, MD, PhD (Moderator)
3:30 PM	Closing Remarks	 Executive Director, RADARS® System – Denver Health and Hospital Authority